Lb Pharmaceuticals (LBRX) Equity Ratio (2024 - 2026)

Lb Pharmaceuticals has reported Equity Ratio for 3 years, with the latest figure at 0.96 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio changed N/A year-over-year to 0.96; the trailing twelve-month figure through Mar 2026 stood at 0.96 (changed N/A YoY), and the FY2025 full-year result was 0.96, up 134.15% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.96, roughly flat from 0.96 in the prior quarter.
• The five-year high for Equity Ratio was 0.97 in Q3 2025, with the low at 2.82 in Q4 2024.
• Average Equity Ratio over 3 years is 0.02, with a median of 0.96 recorded in 2025.
• Peak annual rise in Equity Ratio reached 134.15% in 2025, while the deepest fall reached 134.15% in 2025.
• Tracing LBRX's Equity Ratio over 3 years: stood at 2.82 in 2024, then jumped by 134.15% to 0.96 in 2025, then retreated by 0.05% to 0.96 in 2026.
• The last three Equity Ratio figures came in at 0.96 (Q1 2026), 0.96 (Q4 2025), and 0.97 (Q3 2025), per Business Quant data.

Peer Comparison